Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer;Toxicidad cutánea asociada a cetuximab en cáncer colorrectal metastásico

Farmacia Hospitalaria

Volumn 35, Issue 3, 2011, Pages 114-120

  Rodriguez Murphy E ^a   Villanueva Herraiz, S ^a   Ortega Garcia M P ^a   Perez Feliu A ^a   Lopez Montenegro Soria M A ^b   Camps Herrero, C ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Acneiform eruption; Cetuximab; Metastatic colorectal cancer; Skin toxicity; Treatment protocol

Indexed keywords

CETUXIMAB;

ACNE; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONJUNCTIVITIS; DATA BASE; DRUG SAFETY; EYELASH; FOOT DISEASE; FOOT FISSURE; HAIR GROWTH; HAND DISEASE; HAND FISSURE; HUMAN; MEDICAL RECORD REVIEW; NATIONAL HEALTH ORGANIZATION; PARONYCHIA; PATIENT EDUCATION; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; TREATMENT DURATION; XEROSIS;

ACNEIFORM ERUPTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 79956077166     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.1016/j.farma.2010.10.004     Document Type: Article

References (29)

1. Ficha técnica Erbitux®.
2. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magné N, Milano G. Pharmacological background of EGFR targeting. Ann Oncology. 2004;15:1007-12. (Pubitemid 39089775)
3. Carnero Gómez R. Impacto del tratamiento del cáncer colorrectal metastásico con Erbitux (cetuximab). Rev Esp Econ Salud. 2005;4:179-82.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med. 2008;359:1757-65.
5. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009;16:16-26.
6. Guhl G, González-de Arriba A, Daudén E. Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico. Actas Dermosifiliogr. 2006;97:296-310. (Pubitemid 44125127)
7. Segaert S, Tabernero J, Chosidow O, Dirshka T, Elsner J, Mancini L, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. JDDG. 2005;3:599-606. (Pubitemid 41647826)
8. Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Letter. 2007;12:1-5.
9. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol. 2009;4:107-19.
10. Roé E, García MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. JAAD. 2006;55:429-37. (Pubitemid 44189595)
11. Wolf FI, Trapani V, Cittadini A, Maier JAM. Hypomagnesaemia in oncologic patients:to treat or not to treat? Magnesium Research. 2009;22:5-9.
12. Wolf FI, Cittadini ARM, Maier JAM. Magnesium and tumors: ally or foe? Cancer Treat Rev. 2009;35:378-82.
13. Chua W, Peters M, Loneragan R, Clarke S. Cetuximab-associated pulmonary toxicity. Clin Colorectal Cancer. 2009;8:118-20.
14. Chung CH. Managing premedications and the risk of reactions to infusional monoclonal antibody therapy. The Oncologist. 2008;13:725-32.
15. Melichar B, Cerman J, Malířová E. Successful management of infusion reaction accompanying the start of cetuximab therapy. Support Care Cancer. 2007;15:445-9. (Pubitemid 46697013)
16. Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice:results of a multicenter study. Support Care Cancer. 2009;17:91-8.
17. National Cancer Institute Common Toxicity Criteria, Version 4.0; May 2009 [consultado 13/3/2010]. Disponible en: http://ctep.cancer.gov/reporting/ctc. htlm.
18. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169-76. (Pubitemid 34204207)
19. Herrera-Acosta E, Martín-Ezquerra G, Iglesias M, Umbert P. Erupción acneiforme secundaria a cetuximab. Actas Dermosifiliogr. 2005;96:252-4.
20. Walon L, Gilbeau C, Lachapelle JM. Éruptions acnéiformes induites par le cétuximab. Ann Dermatol Venereol. 2003;130:443-6. (Pubitemid 36723277)
21. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Br J Dermatol. 2004;151:238-41. (Pubitemid 39061311)
22. Martínez de Lagrán Z, Ratón JA, Lasa O, Acebo E, Díaz-Pérez JL, et al. Erupción acneiforme por inhibidores del receptor de crecimiento epidérmico. Actas Dermosifiliogr. 2005;96:450-4. (Pubitemid 41512528)
23. Gridelli C, Maione P, Amorosob D, Baldari M, Bearz A, Bettoli V, et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol/Hematol. 2008;66:155-62.
24. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncology. 2005;16:1425-33. (Pubitemid 41222414)
25. Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol. 2009;61:614-20.
26. Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Massutí Sureda B, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR Inhibitor Rash Management Forum. The Oncologist. 2005;10:345-56. (Pubitemid 40647253)
27. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a Phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-7.
28. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized doubleblind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390-6. (Pubitemid 350232214)
29. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes:results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113:847-53.